Avatar

Clinical Trials in Myeloma in 2018

By Krina Patel 4 Videos
June 22, 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Scripps MD Anderson Cancer Center

Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology 2021

Sat, Feb 20, 2021
The Royal Marsden School

Demystifying the Science Behind Targeted Treatments for Haematological C...

Tue, Feb 2, 2021
Total Health Conferencing

Virtual West Oncology Conference

Fri, Feb 26, 2021
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
14:16
2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do T...

Feat. K. Anderson
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs, mSMART Classi...

13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussi...

Feat. M. Leukam
23:48
UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Res...

Feat. J. Jasielec
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

06:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in ...

Feat. F. Anwer
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
27:06
UChicago CAR T-Cell Symposium 2019

Why Does CAR T-Cell Therapy Fail? An Update on Mechanisms of Resistance/...

Feat. J. Kline
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
07:57
Penn Medicine 2020 Updates in Oncology

ASCO Update on Myeloma: How Promising Are BCMA CAR-T & BCMA x CD3 Bispec...

Feat. D. Vogl
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma